Generic Injectables Market

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
Generic Injectables Market contains market size and forecasts of Generic Injectables in Global, including the following market information:
Global Generic Injectables Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Generic Injectables market was valued at 31500 million in 2021 and is projected to reach US$ 39670 million by 2028, at a CAGR of 3.3% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Small Molecule Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Generic Injectables include Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy?s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical and Auromedics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Generic Injectables companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Generic Injectables Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Generic Injectables Market Segment Percentages, by Type, 2021 (%)
Small Molecule
Large Molecule
Global Generic Injectables Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Generic Injectables Market Segment Percentages, by Application, 2021 (%)
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
Global Generic Injectables Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Generic Injectables Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Generic Injectables revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Generic Injectables revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy?s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC